Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
82.62
+0.25 (0.30%)
Oct 12, 2026, 10:48 AM EDT - Market open
Dianthus Therapeutics Stock Forecast
Stock Price Forecast
According to 16 analysts polled by S&P Global, Dianthus Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $140.8. The average 1-year stock price forecast is 70.42% higher than the current stock price, while the lowest is $122 (+47.66%) and the highest is $200 (+142.07%).
Price Target: $140.8 (+70.42%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Dianthus Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 15 | 15 | 15 | 16 | 15 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 15 | 17 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $158 | Buy | Reiterates | $158 | +91.24% | Oct 1, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $125 | Buy | Maintains | $125 | +51.30% | Sep 29, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 24, 2026 |
| William Blair | William Blair | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 18, 2026 |
| Citi | Citi | Buy Initiates $156 | Buy | Initiates | $156 | +88.82% | Sep 4, 2026 |
Financial Forecast
Revenue This Year
1.87M
from 2.04M
Decreased by -8.16%
Revenue Next Year
1.77M
from 1.87M
Decreased by -5.08%
EPS This Year
-3.81
from -4.20
EPS Next Year
-4.61
from -3.81
EPS and Forward PE are based on non-GAAP adjusted numbers.